Therefore, BRAF mutational status determination is mandatory in AM patients due to its predictive value of response to BRAF and MEK inhibitors, although these patients can also benefit from immune checkpoint inhibitors (ICIs) [12]. Here, BRAF is linked to acute myeloblastic leukemia with maturation.